NCT00192335View on ClinicalTrials.gov

Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants

PHASE3CompletedINTERVENTIONAL
Enrollment

890

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

February 28, 2005

Conditions
Healthy
Interventions
BIOLOGICAL

CAIV-T

BIOLOGICAL

CAIVT

The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).

BIOLOGICAL

FluMist

The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).

Trial Locations (3)

40004

Kentucky Pediatric/Adult Research, Inc., Bardstown

66216

Heart of America Research Institute, Shawnee Mission

77566

R/D Clinical Research, Inc., Lake Jackson

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY